DEVA ABOUT US
Established in 1958, DEVA Holding is one of the well-established pharmaceutical companies in Turkey.
With the main area of operations including manufacturing and marketing medicinal products for human and use and raw materials, DEVA Holding also manufactures veterinary medicines, eau de Cologne, and medical ampoules.
The majority of shares in DEVA Holding was acquired in 2006 by funds managed by GEM Global Equities Management S.A., an international fund management company, and EastPharma Ltd. was established to assume management.
DEVA holding is pacing rapidly toward its goal of being the first choice by offering innovative and unique products with a high-quality experience by creating giant pharmaceutical brands in areas where it competes, in order to make healthy living accessible to everyone around the world. DEVA Holding places new products on the market every year to diversify its offering and make a difference. Currently, DEVA Holding has approximately 400 products in its portfolio, spanning 13 different therapeut fields, ranging from oncology to cardiology and from the respiratory system to ophthalmology.
With progressively expanding regional growth and export operations, DEVA Holding is the holder of more than 500 marketing authorizations in over 50 countries, including the USA, Switzerland, Germany, Netherlands and the UK.
DEVA Holding focuses on research and development to improve access to medicines for patients who need them, and its manufacturing facilities are certified compliant with the European GMP (Good Manufacturing Practice) and the US FDA (Food and Drug Administration) requirements, with the first export to the USA already accomplished.
DEVA Holding develops high added value, innovative new forms and products with its highly-competent staff of experts trained in their areas and experienced in R&D in its full-fledged laboratories and manufacturing areas equipped with state-of-the-art technology at its award-winning DEVARGE Center.
With its manufacturing capabilities, DEVA Holding has become the domestic corporation with the most comprehensive production capabilities in Turkey. Undertaking manufacturing operations at facilities in Çerkezköy and Kartepe, DEVA Holding holds an annual output capacity of 515 million units of medicines.
Continuing to work for a healthier future, DEVA Holding also supports social responsibility projects.
Notes From The Pharmaceutical Industry
According to free market and overall tender data of IMS Health, 2,387 million units and TL 26.4 billion (*) worth of medicines were sold in Turkish Pharmaceutical Market in 2017. The market achieved growth at a rate of 3.92% in number of units and at a rate of 20.50% in TL compared with the previous year.
Rate of prescription drugs to total pharmaceutical market in Turkish market is 93.3% in number of units and 92.8% in TL.
Although drugs from many treatment groups are imported in our country, preparations requiring new and advanced technology, nervous system drugs, blood factors, some controlled-release drugs, insulin, and anti-cancer drugs are predominantly imported.
According to IMS Health data, the sector’s import increased by 6% on a unit basis and decreased by 0.7%, resulting in USD 4.1 billion on USD basis in 2017. The domestic pharmaceutical market grew by 3.3% on a unit basis and increased by 0.3% on USD basis, reaching USD 3,1 billion on USD basis. The rate of import to the total pharmaceutical market is 24% on a unit basis and 57% on USD basis.
According to IMS Health data, the sector grew by 3.92% on a unit basis and shrunk by 0.3% on USD basis, resulting in USD 7.2 billion in 2017. The total pharmaceutical market reached TL 20,50 billion, with a growth of 26.4%.
(*) “Surplus Goods” are included in the value in units but not included in the value in TL depending on the change in the calculation method of the IMS.
Market distribution according to drug segments in our country in 2017 took place on unit and TL/USD basis as follows. On both unit and TL/USD basis, Nutrition & Metabolism segment has the biggest share.
Source: IMS Health Free +Tender Dataview
We exist to offer innovative and diversified rang of products with a high quality experience enabling healthy life opportunity to be available to everyone on a global scale.
To become the first choice by creating robust pharmaceutical brands in the areas we compete in.
• Innovation and development
• Human focus
DEVA QUALITY CULTURE
QUALITY – CARE & INNOVATION
DEVA quality reflects two fundamental principles of CARE and INNOVATION.
We care for our patients, customers, partners, employees and environment in which we manufacture our products. In taking care we provide a secure and ethical supply of products to underpin the DEVA brand and reputation.
We innovate our products, processes and management practices to enable our company to continously improve our service, our market share and to hold a competitive advantage. Through our innovative approaches we are able to maximiseshare holder investments.
QUALITY – CULTURE
DEVA quality culture is founded upon the concept of “Right first time”. Each and every employee at DEVA adopts it as a principle to ensure patient safety and excellence in operations.
DEVA quality culture starts with product research and development and covers all processes from production through to our distribution networks.
QUALITY - SYSTEM
DEVA quality management system ensures our care and innovative principles link directly to our quality culture. Our quality management system provides a framework of operational procedures that bring consistency and best practice to all of our manufacturing sites and also satisfies legal requirements and international levels of Good Manufacturing Practice (GMP). Throughout the quality management system risk managment techniques and pragmatic application exists.
QUALITY – UNDERSTANDING
DEVA is driven by people with passion and understanding. In all aspects of our products DEVA employees strive for improvement and to seek out competitive advantage in both Turkey and International markets. Our people are dedicated and determined to match the challenges facing the pharmaceutical markets.
DEVA BOARD OF DIRECTORS
President of the Board of Directors and CEO
Philipp Haas, Chairman of Board of Directors and CEO of DEVA Holding, took his MBA with a major in banking from St. Gallen Economy, Law and Business Administration University. He is fluent in German, English, French, Spanish, Portuguese, Italian and Turkish. Philipp Haas who has been working as investment advisor and manager since 1992 has a broad experience in the Eastern European countries and Turkey in particular. Having taken part in several restructuring projects in Ukraine and Turkey, Philipp Haas acted as member of several board of directors as representative of foreign corporate investors during the 90s, and Rogan Brewery of Ukraine and Net Holding of Turkey may be mentioned among others. Philipp Haas who has had a vast experience in pharmaceutical industry has provided funds with pharmaceutical industry advisory and helped them direct their investments into Eastern Europe. These included Slovakopharma which changed its name to Zentiva subsequently. Currently serving as Chairman of Board of Directors of EastPharma Ltd., DEVA Holding, Saba İlaç Sanayi ve Ticaret A.Ş., New Life Yaşam Sigorta A.Ş., EastPharma İlaç Üretim Pazarlama San. ve Tic. A.Ş. and a member of Board of Directors at EastPharmaSarl. He also serves as a director in Devatis Limited, Devatis Gmbh, Devatis A.G and Devatis Inc. Philipp Haas is Vice Chairman of the Board of Directors at Pharmaceutical Manufacturers Association of Turkey (TISD).
Deputy Chairman of the BOD and CFO
The Deputy Chairman of the Board of Directors and CFO of DEVA Holding, Mesut Çetin worked as director responsible for operations within GEM Global Equities Management S.A. 2005 and 2007 and has served in various positions within the same group as analyst, trader and project manager since 1999.Mesut Çetin is the member of the BOD in EastPharma Ltd. Saba İlaç Sanayi ve Ticaret A.Ş. He also performs the duty of CFO in various companies within the group. Mesut Çetin is the graduate of Mathematics in Boğaziçi University and continues the EMBA program in Koç University.
Member of the Board of Directors
Güneş Ufuk, an independent director of the Board of Directors of DEVA Holding, had worked within the sales and marketing departments of a number of Swiss companies after studying at the faculty of Business of Administration, St. Gallen University in Switzerland. He also worked in top management functions at Kemer Golf&Country Club, Superonline and YKS (which is also an affiliate of the Çukurova Group of Companies).
Upon putting an end to his professional career at Kemer Golf & Country Club while working as in General Manager Position, Ufuk started a new career as a consultant. He had worked as an Executive Officer and Consultant within MCT Company for over 6 years; and then founded k2 Consulting Company in April 2010 and provided various companies in Turkey with Management Consultation service as a Trainer and Speaker. By providing services with his k2 Consultancy team to 100+ leading companies operating in various areas in Turkey, Ufuk has become an expert in the fields of “Sales and Marketing”, “Leadership” and “Strategy”.
He is one of the founding partners of K2C Consulting Company which was founded in 2015, and continues his operations at K2C Consulting Company.
Member of the Board of Directors
Being the Non-Executive Member of the Board of Directors of DEVA Holding, Ayşecik Haas completed her license degree in Electrical-Electronic Engineering in Doğu Akdeniz University after graduating Ankara Private Yükseliş College in 1991, then took her master degree in Economics branch in Texas Tech University.
Having commenced the work life at various positions relating to engineering in Emek Elektrik and Beko Elektronik in Turkey, Ayşecik Haas worked in finance sector in New York after taking Economy Master degree after which she worked as investment specialist in Hattat Holding for a short period of time. Having commenced to perform as General Manager of NAR Group, a media company, in 2008, Ayşecik Haas is currently continuing this task.
Tuncay Cem Akkuş
Member of the Board of Directors
Independent Member of the Board of Directors, has a bachelor’s degree in the department of Electric-Electronical Engineering of East Mediterranean University.
He started his career with General Directorate of PTT as system engineer and after a short time he worked in the telecommunication sector. In this sector, he worked with, respectively, Siemens A.Ş, Sabancı Telekom, Global İletişim, Turkcell Superonline and finally Millenicom as a manager on engineering and infrastructure project in operation department.
DEVA HEALTH, SAFETY AND ENVIRONMENTAL POLICY
Our aim is to ensure environmental regulations, occupational regulations, local requirements and stakeholder expectations;
To ensure that we keep under control the effects of our productions of health- safety-environment and to use appropriate Technologies and to endeavor to not occur accidents and occupational diseases.
To ensure that we give to our workers and stakeholders educations to raise their health-safety-environment behaviour.
To ensure sustainability environment that we give to our workers and stakeholders educations to raise their health-safety-environment behaviour.
Our aim is to ensure that we are the model firm about health-safety-environment.
To undertake that this policy is revised to prevent hazards which cause accidents and occupational diseases with our systems.
Philipp Haas Mesut Çetin
C Chairman of the Board of Directors and CEO Deputy Chairman of the BOD and CFO
DEVA SHAREHOLDING STRUCTURE AND SUBSIDIARIES